Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ:ABSI)

3.095 +0.085 (+2.82%)
Streaming Delayed Price Updated: 12:36 PM EDT, Mar 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Absci Corporation - Common Stock

< Previous 1 2 3 Next >
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
From Absci Corporation
Via GlobeNewswire
Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 26th Annual Needham Growth Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
From Absci Corporation
Via GlobeNewswire
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci’s AI Antibody Drug Creation Platform with AstraZeneca’s Expertise in Oncology Research and Development 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
From Almirall S.A.
Via Business Wire
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
From Absci Corporation
Via GlobeNewswire
Absci to Host R&D Day on October 4, 2023
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci’s next stage of growth 
From Absci Corporation
Via GlobeNewswire
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Canaccord Genuity 43rd Annual Growth Conference
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
From Absci Corporation
Via GlobeNewswire
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies
Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapies 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology
Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments faster 
From Absci Corporation
Via GlobeNewswire
Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation
From Absci Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.